Reduced tolerogenic factor sCD83 in NMOSD and relapsing MOGAD: a potential new therapeutic pathway
Our study consistently found lower sCD83 levels in NMOSD and relapsing MOGAD patients. sCD83 levels increased following IVIG and immunosuppressive therapy. This elevation may reflect either a direct effect of the therapy itself, or a compensatory rebound response following immune suppression. These findings highlight the potential of sCD83 as a prognostic biomarker in these diseases and support its role as both a therapeutic target and a marker for treatment response in CNS demyelinating disorders.
Authors
- Livnat Brill (ORCID: https://orcid.org/0000-0002-1950-4933)
- Tal Friedman‐Korn
- Ariel Rechtman (ORCID: https://orcid.org/0000-0003-0968-3576)
- Omri Zveik (ORCID: https://orcid.org/0000-0002-8878-4211)
- Adi Vaknin‐Dembinsky (ORCID: https://orcid.org/0000-0001-8322-1252)
- Lyne Shweiki
- Garrick Hoichman
Institutions
- Hebrew University of Jerusalem (IL)
- Hadassah Medical Center (IL)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-07-24
- DOI
- https://doi.org/10.3389/fimmu.2025.1620069
- Citations
- 1
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47